EDF1

Summary

EDF1 (endothelial differentiation related factor 1, HGNC:3164) is a protein-coding gene on chromosome 9q34.3, encoding Endothelial differentiation-related factor 1 (O60869). Transcriptional coactivator stimulating NR5A1 and ligand-dependent NR1H3/LXRA and PPARG transcriptional activities.

This gene encodes a protein that may regulate endothelial cell differentiation, lipid metabolism, and hormone-induced cardiomyocyte hypertrophy. The encoded protein has also been found to act as a transcriptional coactivator by interconnecting the general transcription factor TATA element-binding protein (TBP) and gene-specific activators. Alternate splicing results in multiple transcript variants.

Source: NCBI Gene 8721 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 21 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_003792

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3164
Approved symbol	EDF1
Name	endothelial differentiation related factor 1
Location	9q34.3
Locus type	gene with protein product
Status	Approved
Aliases	EDF-1, CFAP280
Ensembl gene	ENSG00000107223
Ensembl biotype	protein_coding
OMIM	605107
Entrez	8721

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000224073, ENST00000371648, ENST00000371649, ENST00000881208, ENST00000881209, ENST00000881210, ENST00000936807

RefSeq mRNA: 5 — MANE Select: NM_003792 NM_001281297, NM_001281298, NM_001281299, NM_003792, NM_153200

CCDS: CCDS65193, CCDS7011, CCDS7012

Canonical transcript exons

ENST00000224073 — 5 exons

Exon	Start	End
ENSE00000733887	136863288	136863448
ENSE00000870750	136863820	136863871
ENSE00000870751	136862119	136862345
ENSE00001042853	136866181	136866308
ENSE00001364523	136862906	136862999

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 99.49.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 447.4172 / max 1577.4517, expressed in 1828 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
103230	367.5183	1828
103228	43.4167	1820
103229	36.4823	1821

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	99.49	gold quality
adenohypophysis	UBERON:0002196	99.47	gold quality
body of pancreas	UBERON:0001150	99.45	gold quality
right lobe of thyroid gland	UBERON:0001119	99.44	gold quality
left lobe of thyroid gland	UBERON:0001120	99.43	gold quality
mucosa of transverse colon	UBERON:0004991	99.42	gold quality
duodenum	UBERON:0002114	99.39	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.37	gold quality
pituitary gland	UBERON:0000007	99.36	gold quality
jejunal mucosa	UBERON:0000399	99.35	gold quality
cerebellar cortex	UBERON:0002129	99.34	gold quality
cerebellar hemisphere	UBERON:0002245	99.34	gold quality
body of stomach	UBERON:0001161	99.33	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	99.32	gold quality
left adrenal gland	UBERON:0001234	99.31	gold quality
left ovary	UBERON:0002119	99.31	gold quality
left adrenal gland cortex	UBERON:0035825	99.31	gold quality
skin of abdomen	UBERON:0001416	99.30	gold quality
small intestine Peyer’s patch	UBERON:0003454	99.30	gold quality
saliva-secreting gland	UBERON:0001044	99.29	gold quality
right adrenal gland	UBERON:0001233	99.29	gold quality
right frontal lobe	UBERON:0002810	99.29	gold quality
anterior cingulate cortex	UBERON:0009835	99.29	gold quality
granulocyte	CL:0000094	99.28	gold quality
right ovary	UBERON:0002118	99.28	gold quality
cingulate cortex	UBERON:0003027	99.28	gold quality
metanephros cortex	UBERON:0010533	99.28	gold quality
apex of heart	UBERON:0002098	99.27	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	99.27	gold quality
skin of leg	UBERON:0001511	99.26	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-130148	yes	4.51
E-GEOD-109979	no	208.93
E-GEOD-125970	no	74.34
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA4, SP1, SP3, TBP

miRNA regulators (miRDB)

24 targeting EDF1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-4708-3P	99.51	67.99	870
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-6165	99.44	67.12	1389
HSA-MIR-329-5P	99.27	68.11	1597
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-1207-3P	98.99	66.22	1532
HSA-MIR-1304-5P	98.90	68.58	1054
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-761	98.71	68.07	2051
HSA-MIR-3188	98.58	65.60	878
HSA-MIR-5008-5P	98.42	65.87	1019
HSA-MIR-514A-3P	96.43	67.77	1048
HSA-MIR-514B-3P	96.43	67.77	1048
HSA-MIR-6765-5P	94.51	62.65	164
HSA-MIR-2277-3P	91.94	62.27	299
HSA-MIR-6089	89.72	61.35	324

Literature-anchored findings (GeneRIF, showing 5)

• Multiprotein bridging factor-1 (MBF-1) is a cofactor for nuclear receptors that regulate lipid metabolism. (PMID:12040021)
• The EDF-1 minimal promoter was characterized. (PMID:16567061)
• According to this study multiprotein bridging factor 1 and Calmodulin do not interact in vitro as confirmed by NMR spectroscopy and CaM-agarose affinity chromatography. (PMID:21782027)
• EDF1 is required for VEGF-induced activation of the transcriptional activity of PPARgamma in HUVEC cells. (PMID:29933613)
• EDF1 coordinates cellular responses to ribosome collisions. (PMID:32744497)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	edf1	ENSDARG00000009950
mus_musculus	Edf1	ENSMUSG00000015092
rattus_norvegicus		ENSRNOG00000084601
drosophila_melanogaster	mbf1	FBGN0262732
caenorhabditis_elegans		WBGENE00003148

Protein

Protein identifiers

Endothelial differentiation-related factor 1 — O60869 (reviewed: O60869)

Alternative names: Multiprotein-bridging factor 1

All UniProt accessions (1): O60869

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional coactivator stimulating NR5A1 and ligand-dependent NR1H3/LXRA and PPARG transcriptional activities. Enhances the DNA-binding activity of ATF1, ATF2, CREB1 and NR5A1. Regulates nitric oxid synthase activity probably by sequestering calmodulin in the cytoplasm. May function in endothelial cells differentiation, hormone-induced cardiomyocytes hypertrophy and lipid metabolism.

Subunit / interactions. Interacts with TBP and the transcription factor IID (TFIID) complex, NR5A2, NR1H3 and PPARG. Interaction with TBP is regulated by phosphorylation. Binds NR5A1, ATF1, FOS and JUN via their conserved basic region. Binding to calmodulin is regulated by calcium and phosphorylation of the IQ motif.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expressed in brain, liver, lung, kidney and heart (at protein level). Ubiquitously expressed. More abundant in heart, pancreas, liver, intestine and adipose tissues.

Post-translational modifications. Phosphorylated (by PKA and PKC).

Domain organisation. The IQ motif, which is involved in calmodulin binding, overlaps with the binding domain for nuclear receptors and transcription factors. Its phosphorylation probably allows a switch between the two activities of the protein.

Induction. Down-regulated by HIV-1 Tat or phorbol ester (TPA) treatment in endothelial cells (at mRNA and protein levels).

Isoforms (3)

UniProt ID	Names	Canonical?
O60869-1	1, Alpha	yes
O60869-2	2, Beta
O60869-3	3

RefSeq proteins (5): NP_001268226, NP_001268227, NP_001268228, NP_003783, NP_694880 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001387	Cro/C1-type_HTH	Domain
IPR010982	Lambda_DNA-bd_dom_sf	Homologous_superfamily
IPR013729	MBF1_N	Domain

Pfam: PF01381, PF08523

UniProt features (33 total): mutagenesis site 9, helix 6, modified residue 3, region of interest 3, splice variant 2, turn 2, compositionally biased region 2, initiator methionine 1, chain 1, domain 1, DNA-binding region 1, strand 1, short sequence motif 1

Structure

Experimental structures (PDB)

9 structures.

PDB	Method	Resolution (Å)
9RPV	ELECTRON MICROSCOPY	2.35
9P73	ELECTRON MICROSCOPY	2.66
6ZVH	ELECTRON MICROSCOPY	2.9
9P8H	ELECTRON MICROSCOPY	2.98
9B0Q	ELECTRON MICROSCOPY	3.2
9B0S	ELECTRON MICROSCOPY	3.8
1X57	SOLUTION NMR
9AZN
9B0W

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60869-F1	83.47	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 2, 4, 25

Mutagenesis-validated functional residues (9):

Position	Phenotype
40	loss of interaction with calm; when associated with d-58; d-91 and d-111.
58	loss of interaction with calm; when associated with d-40; d-91 and d-111.
65	no effect on calm-binding. no effect; when associated with d-74.
74	no effect on calm-binding. no effect; when associated with d-65.
87	no effect on calm-binding.
87	loss of interaction with calm and higher affinity for tbp. same effect; when associated with d-65 and d-74.
91	no effect on calm-binding.
91	partial loss of interaction with calm. complete loss of interaction; when associated with d-40; d-58 and d-111.
111	loss of interaction with calm; when associated with d-40; d-58 and d-91.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 91 (showing top): GOBP_EPITHELIUM_DEVELOPMENT, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_10, GCANCTGNY_MYOD_Q6, CAGCTG_AP4_Q5, GOBP_POSITIVE_REGULATION_OF_BINDING, GOBP_REGULATION_OF_LIPID_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_ENDOTHELIUM_DEVELOPMENT, GOBP_LIPID_METABOLIC_PROCESS, SCHLINGEMANN_SKIN_CARCINOGENESIS_TPA_UP, OSMAN_BLADDER_CANCER_DN, KIM_WT1_TARGETS_DN, GOBP_REGULATION_OF_DNA_BINDING, MATSUDA_NATURAL_KILLER_DIFFERENTIATION

GO Biological Process (6): regulation of DNA-templated transcription (GO:0006355), regulation of lipid metabolic process (GO:0019216), positive regulation of DNA binding (GO:0043388), endothelial cell differentiation (GO:0045446), positive regulation of DNA-templated transcription (GO:0045893), cell differentiation (GO:0030154)

GO Molecular Function (6): TFIID-class transcription factor complex binding (GO:0001094), DNA binding (GO:0003677), transcription coactivator activity (GO:0003713), RNA binding (GO:0003723), calmodulin binding (GO:0005516), protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytoplasm (GO:0005737), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
DNA-templated transcription	2
nucleic acid binding	2
nuclear lumen	2
regulation of gene expression	1
regulation of RNA biosynthetic process	1
lipid metabolic process	1
regulation of primary metabolic process	1
DNA binding	1
positive regulation of binding	1
regulation of DNA binding	1
endothelium development	1
epithelial cell differentiation	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
cellular developmental process	1
RNA polymerase II general transcription initiation factor binding	1
transcription coregulator activity	1
positive regulation of DNA-templated transcription	1
protein binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

2894 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EDF1	TBP	P20226	808
EDF1	NR5A2	O00482	731
EDF1	ZNF598	Q86UK7	662
EDF1	NR5A1	Q13285	628
EDF1	GIGYF2	Q6Y7W6	550
EDF1	CALML3	P27482	528
EDF1	CALML6	Q8TD86	528
EDF1	CALML4	Q96GE6	528
EDF1	CALML5	Q9NZT1	528
EDF1	RPS20	P17075	481
EDF1	HBS1L	Q9Y450	464
EDF1	NFYB	P25208	419
EDF1	PRRC2C	Q9Y520	416
EDF1	ZC3H11A	O75152	412
EDF1	CLPB	Q9H078	403

IntAct

76 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
EDF1	ESR1	psi-mi:“MI:0407”(direct interaction)	0.590
EDF1	NR1H3	psi-mi:“MI:0915”(physical association)	0.580
EDF1	PPARG	psi-mi:“MI:0915”(physical association)	0.580
PPARG	EDF1	psi-mi:“MI:0915”(physical association)	0.580
MEOX2	EDF1	psi-mi:“MI:0915”(physical association)	0.560
EDF1	HTT	psi-mi:“MI:0915”(physical association)	0.560
CFTR	EDF1	psi-mi:“MI:0915”(physical association)	0.520
NS	EDF1	psi-mi:“MI:0915”(physical association)	0.510
EDF1	NS	psi-mi:“MI:0915”(physical association)	0.510
DDX21	MED19	psi-mi:“MI:2364”(proximity)	0.480
H3C1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.410
ZNF157	EDF1	psi-mi:“MI:0915”(physical association)	0.400
GTF3C1	EDF1	psi-mi:“MI:0915”(physical association)	0.400
DDX52	EDF1	psi-mi:“MI:0915”(physical association)	0.400
	FER1L5	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (110): EDF1 (Two-hybrid), EDF1 (Affinity Capture-RNA), EDF1 (Two-hybrid), DNAJB1 (Co-fractionation), EDF1 (Co-fractionation), EDF1 (Co-fractionation), EDF1 (Co-fractionation), HNRNPF (Co-fractionation), EDF1 (Proximity Label-MS), EDF1 (Proximity Label-MS), EDF1 (Affinity Capture-MS), EDF1 (Affinity Capture-MS), EDF1 (Affinity Capture-MS), EDF1 (Affinity Capture-RNA), EDF1 (Affinity Capture-MS)

ESM2 similar proteins: A4RHN3, A6SGN8, A7EWN6, G0S8F1, G1TDB3, O14467, O60869, O94659, O94700, P0CO30, P0CO31, P14327, P48588, P62851, P62852, P62853, P69736, Q2H0U6, Q2UGU3, Q3T0V7, Q4HYB8, Q4I5I4, Q4WX89, Q52BY4, Q53IP3, Q56JX5, Q5A940, Q5B8Y4, Q5ZMC0, Q6BXQ8, Q6CIP4, Q6FJN0, Q6GPQ6, Q6MFP4, Q6PBI5, Q6PBY3, Q6Q311, Q74ZK6, Q752P7, Q7S3C4

Diamond homologs: O14467, O60869, O94700, P0CO30, P0CO31, P14327, P69736, Q3T0V7, Q4WX89, Q52BY4, Q53IP3, Q5A940, Q5B8Y4, Q5ZMC0, Q6BXQ8, Q6CIP4, Q6FJN0, Q6GPQ6, Q6PBY3, Q752P7, Q871W6, Q8TG23, Q9JMG1, Q9LV58, Q9LXT3, Q9SJI8, O30257

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
PRKCA	“down-regulates activity”	EDF1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 70 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SUMOylation of intracellular receptors	6	37.3×	6e-06
Nuclear Receptor transcription pathway	6	22.3×	8e-05
SARS-CoV-1-host interactions	5	16.3×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
hormone-mediated signaling pathway	5	32.4×	2e-04
mRNA transcription by RNA polymerase II	5	26.6×	3e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

21 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	12
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
59136	GRCh38/hg38 9q34.2-34.3(chr9:134428674-138154922)x1	Pathogenic

SpliceAI

1237 predictions. Top by Δscore:

Variant	Effect	Δscore
9:136862996:TTTT:T	acceptor_gain	1.0000
9:136862997:TTTCT:T	acceptor_loss	1.0000
9:136862998:TT:T	acceptor_gain	1.0000
9:136862999:TC:T	acceptor_loss	1.0000
9:136863000:C:CC	acceptor_gain	1.0000
9:136863000:CTAA:C	acceptor_loss	1.0000
9:136863001:T:C	acceptor_loss	1.0000
9:136863284:TCA:T	donor_loss	1.0000
9:136863285:CACCG:C	donor_loss	1.0000
9:136863286:A:C	donor_loss	1.0000
9:136863287:C:A	donor_loss	1.0000
9:136863309:AAGCC:A	donor_gain	1.0000
9:136863456:C:CT	acceptor_gain	1.0000
9:136863457:G:T	acceptor_gain	1.0000
9:136863458:G:C	acceptor_gain	1.0000
9:136863458:G:GC	acceptor_gain	1.0000
9:136863460:G:C	acceptor_gain	1.0000
9:136863460:G:GC	acceptor_gain	1.0000
9:136863466:C:CT	acceptor_gain	1.0000
9:136863467:A:T	acceptor_gain	1.0000
9:136863818:A:AC	donor_gain	1.0000
9:136863819:C:CC	donor_gain	1.0000
9:136863819:CATTT:C	donor_gain	1.0000
9:136863868:TAGC:T	acceptor_gain	1.0000
9:136863872:C:CA	acceptor_loss	1.0000
9:136863872:C:CC	acceptor_gain	1.0000
9:136863873:T:A	acceptor_loss	1.0000
9:136863880:T:TC	acceptor_gain	1.0000
9:136866176:AGCAC:A	donor_loss	1.0000
9:136866177:GCAC:G	donor_loss	1.0000

AlphaMissense

959 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:136863292:G:T	A96D	1.000
9:136862330:C:T	G134E	0.999
9:136862336:A:T	L132H	0.999
9:136862920:A:T	I124N	0.999
9:136862974:A:T	I106N	0.999
9:136863292:G:A	A96V	0.999
9:136863293:C:G	A96P	0.999
9:136863295:A:G	L95P	0.999
9:136863337:A:T	I81N	0.999
9:136863346:C:T	G78D	0.999
9:136863397:A:G	L61P	0.999
9:136862914:C:G	R126P	0.998
9:136862917:T:A	E125V	0.998
9:136862950:G:T	A114D	0.998
9:136862961:C:A	E110D	0.998
9:136862961:C:G	E110D	0.998
9:136863293:C:T	A96T	0.998
9:136863303:C:A	Q92H	0.998
9:136863303:C:G	Q92H	0.998
9:136863325:C:G	R85P	0.998
9:136863391:C:G	R63P	0.998
9:136863397:A:T	L61Q	0.998
9:136863439:C:T	G47D	0.998
9:136866241:C:A	W6C	0.998
9:136866241:C:G	W6C	0.998
9:136866243:A:G	W6R	0.998
9:136866243:A:T	W6R	0.998
9:136862330:C:A	G134V	0.997
9:136862336:A:G	L132P	0.997
9:136862918:C:T	E125K	0.997

dbSNP variants (sampled 300 via entrez): RS1000069803 (9:136867125 C>T), RS1000120107 (9:136866907 A>G), RS1000576165 (9:136865973 A>C,G), RS1000977063 (9:136862499 A>C,G), RS1001673430 (9:136865377 C>G), RS1001740150 (9:136865552 A>G,T), RS1001944408 (9:136864279 T>A), RS1002583024 (9:136868095 ACT>A), RS1003412265 (9:136864451 C>T), RS1003465014 (9:136864251 G>A), RS1004661930 (9:136864265 A>G), RS1005088729 (9:136867820 C>T), RS1005288329 (9:136866822 C>G), RS1005820532 (9:136863570 G>A,T), RS1006290390 (9:136863191 G>C,T)

Disease associations

OMIM: gene MIM:605107 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL4295670 (SINGLE PROTEIN), CHEMBL4742264 (PROTEIN-PROTEIN INTERACTION)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.84	Kd	1433	nM	CHEMBL5653589
5.84	ED50	1433	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 4 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148283: Binding affinity to human EDF1 incubated for 45 mins by Kinobead based pull down assay	kd	1.4333	uM

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, affects cotreatment, increases methylation, decreases expression	4
sodium arsenite	increases expression	2
FR900359	decreases phosphorylation	1
deoxynivalenol	increases expression	1
pyrogallol 1,3-dimethyl ether	affects localization, increases expression, affects cotreatment	1
afimoxifene	affects response to substance	1
cobaltous chloride	decreases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	decreases methylation	1
ICG 001	increases expression	1
abrine	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Arsenic	affects methylation	1
Diazinon	increases methylation	1
Doxorubicin	increases expression	1
Furaldehyde	affects localization, decreases expression, affects cotreatment	1
Ivermectin	decreases expression	1
Methapyrilene	decreases methylation	1
Ribonucleotides	affects binding	1
Selenium	increases expression	1
Smoke	decreases expression	1
Sodium Chloride	affects cotreatment, affects localization, decreases expression, increases expression	1
Tobacco Smoke Pollution	affects expression	1
Vitamin E	increases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	affects cotreatment, decreases expression	1
Antirheumatic Agents	decreases expression	1
Cadmium Chloride	increases expression	1
beta-Naphthoflavone	affects cotreatment, decreases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118580	Binding	Binding affinity to EDF1 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Cellosaurus cell lines

4 cell lines: 3 embryonic stem cell, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A1D9	SEES3-1V human EDF1, clone1	Embryonic stem cell	Male
CVCL_A1E0	SEES3-1V human EDF1, clone2	Embryonic stem cell	Male
CVCL_A1E1	SEES3-1V human EDF1, clone3	Embryonic stem cell	Male
CVCL_F1PF	HyCyte HEK293T KO-hEDF1	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.